ABSTRACT
INTRODUCTION
Regulatory T cells (Tregs) are immunosuppressive cells with key roles in immune tolerance and immune dysregulation in pathological settings including inflam mation, autoimmunity and cancer [1] . In cancers, Tregs accumulate in peripheral tissues and tumors where, in conjunction with other immunosuppressive cells, they inhibit tumor specific immune responses and contribute to the development of a tolerogenic tumor microenvironment enabling immune evasion [2, 3] . Elevated Treg levels have been reported to correlate with tumor progression, impaired T cell functionality and negative prognosis in different cancers [4] [5] [6] [7] . Given their role in immune evasion and poor clinical outcomes, Tregs have become an important target for novel cancer immunotherapies [3, [8] [9] [10] .
In recent years, it has become increasingly clear that Tregs comprise diverse subsets with distinct phenotypic and functional features [11] [12] [13] [14] [15] . Understanding the role and contribution of specific Treg subsets is critical to harnessing the potential of different therapeutic modalities. Tregs are generally divided into thymicderived Tregs (tTregs) and peripheralinduced Tregs (pTregs), traditionally defined by expression of the forkhead box P3 transcription factor (FoxP3) and IL2 receptor alpha chain (CD25). In addition, two FoxP3 -pTreg subsets have been identified; Tr1 and Th3 cells. Significant efforts have been made into identifying effective markers for Treg subset identification, isolation and therapeutic manipulation [4, 15, 16] . Both CD25 and FoxP3 can be upregulated on nonsuppressive Teff and activated T cells, while FoxP3 as an intracellular marker does not allow Treg isolation [17] . Promising Treg markers include the latestage Treg activation markers, glycoprotein A repetitions predominant (GARP) and latencyassociated peptide (LAP), and the Ikaros zinc finger transcription factor Helios.
Helios has been suggested to play important roles in immune regulation by repressing proapoptotic genes in Tregs, contributing to the development of follicular Tregs, and enhancing Treg function in cooperation with FoxP3 [18, 19] . Despite its seemingly ubiquitous expression, it is accepted that Helios can define highly suppressive Treg subsets in various settings. FoxP3 +/-Helios + Tregs are significantly expanded in the peripheral blood and at tumor sites of various cancers, and have been reported to exhibit enhanced in vitro suppressive activity [20, 21] .
GARP and LAP are wellcharacterized latestage Treg activation markers, and they contribute directly to a contactdependent TGFβmediated suppressive mechanism in Tregs [22, 23] . LAP is a propeptide that binds noncovalently with transforming growth factor beta (TGFβ) forming an inactive latent LAPTGFβ complex, and TGFβ is cleaved from the latent complex releasing active TGFβ [22] . LAP has been utilized to isolate highly suppressive Tregs in in vitro expansion cultures and also from the peripheral blood of cancer patients following CTLA4 immunotherapy [24, 25] . GARP is a transmembrane protein that plays a critical role in the formation and expression of LAPTGFβ complexes by anchoring the complexes to the cell membrane [23] .
We have recently shown that nonactivated FoxP3 -Helios + and activated FoxP3 +/-Helios + CD4 + T cells isolated from the peripheral blood of healthy donors coexpress GARP and LAP [26] . In the current study we report similar observations in T cells isolated from the peripheral blood of patients with pancreatic cancer (PC) and patients with liver metastases from colorectal cancer (LICRC). In addition, we show that FoxP3 
LAP
+ T cells make IL10 but not IFNγ, and they are increased in LICRC patients.
RESULTS

LAP is expressed significantly higher than GARP on activated CD4
+ T cells in healthy donors and pancreatic cancer patients Peripheral blood samples were collected from PC and LICRC patients and chronic pancreatitis (CP) and Healthy donor (HD) controls. as detailed in Table 1 .
We first compared the expression of LAP and GARP, as markers of activated Tregs, on CD4 + T cells isolated from the peripheral blood of HD and PC patients. LAP and GARP were expressed at low levels on CD4 + T cells in the steady state (< 1% for HD and < 2% for PC patients, data not shown). Following in vitro activation with antiCD3/28, both GARP and LAP were significantly up regulated on CD4 + T cells, as expected. However, expression of LAP was higher than GARP on CD4 + T cells. This difference was significant in healthy donors (LAP: 3.15 ± 0.35% vs. GARP 2.46 ± 0.39%; Figure 1A and 1B) and PC patients (LAP: 5.41 ± 0.51% vs. GARP: 4.73 ± 0.52%; Figure 1C and 1D). We then analyzed FoxP3 and LAP coexpression on nonactivated CD4 + T cells ( Figure 2 ). We found that LAP was coexpressed with FoxP3 at very low levels (< 0.2%) on nonactivated CD4
Levels of FoxP3
+ Tregs from HD, CP, PC and LICRC. This is consistent with our recent finding in healthy donors [26] .
Most studies determine Treg levels based on FoxP3 expression. Defining Tregs based on FoxP3 expression alone, there was no significant increase in the FoxP3 
LAP
+ subset was expanded in activated cells both in LICRC (3.63 ± 0.50%) and PC (3.27 ± 0.37%), compared with HD (1.79 ± 0.27%) and CP controls (1.77 ± 0.30%) ( Figure 3D 
Helios
+/-T cell subpopulations in cells isolated from HD, CP, PC and LICRC in nonactivated and activated settings ( Figure 4 ). We previously reported that the expanded FoxP3 + Treg subset from peripheral blood of untreated renal cell carcinoma patients and also following IL2 treatment coexpress Helios [27] . In this study, we found that FoxP3 + Helios + and FoxP3 -Helios + T cell subsets were significantly higher than FoxP3 
+ in healthy donors in the non activated setting ( Figure 5B and [26] ). Herein, we report similar observations in cells isolated from PC ( Figure 5C ) and LICRC patients ( Figure 5D ). Interestingly, levels of Figure 5E ), compared with healthy donors (4.66 ± 0.86%). There was an increase in this Treg subset in PC (9.60 ± 2.36%, Figure 5E ) compared with HD, although this did not reach statistical significance (P = 0.0801).
Following TCR stimulation, GARP/LAP were up regulated on all T cell subsets (FoxP3 
LAP
-and GARP -LAP -T cell subsets produced negligible amounts of IL10 in both HD and LICRC samples.
Interestingly, levels of IL10secreting CD4 + T cells within GARP + LAP + and GARP -LAP + subsets were significantly higher in LICRC patients than HD ( Figure 7C ). The increase in IL10 secretion in LICRC patients was further confirmed by measuring IL10 secretion in the whole CD4 + T cell population ( Figure 8A  and 8B) , thus confirming the immunosuppressive milieu in cancer patients. When LICRC patients were stratified according to TNM staging, CD4 + T cells from LICRC patients with stage III made significantly higher levels of IL10 than patients with stage I and II ( Figure 8C and 8D). Of interest, there was no significant increase in IFNγsecreting CD4
+ T cells between HD and LICRC patients or between LICRC patients with different staging (Figure 8 ).
DISCUSSION
In this study, we found that FoxP3 coexpression of GARP/LAP with Helios is intriguing. Helios + Tregs have been shown to overexpress TGFβ and to exhibit potent TGFβ mediated suppressive activity [21] . While we did not test the suppressive function of Helios +/-T cell subsets, GARP/LAP coexpression could indicate a robust TGFβ mediated suppressive mechanism. There have been limited investigations into GARP/LAP expression with FoxP3 and Helios. GARP and FoxP3 have been proposed to form a positive feedback loop, although more recent work showed that regulation of GARP is independent of FoxP3 and GARP was also shown not to correlate with Helios expression in FoxP3 + T cells [34, 35] . It remains to be confirmed if there is any mechanistic link between GARP/LAP expression and Helios expression.
The increased levels of FoxP3 
Helios
- [27, 36] .
Interestingly, GARP and LAP were expressed at relatively high levels on the FoxP3 -Helios + Treg subset in the nonactivated setting, and they were expanded in LICRC patients (HD: ~5%, LICRC: ~10%). This FoxP3 
LAP
+ Treg subset has not been previously described and could represent the novel FoxP3
-LAP + Treg subset described in previous studies [28, 31] , emphasizing the importance of Helios as a Treg marker. However, the suppressive ability of this Treg subset will need to be confirmed in functional studies.
We also found that cells from LICRC patients secrete more IL10, which is confined to the GARP +/-LAP + Tcell compartments. Interestingly, LICRC patients with higher TNM staging had higher levels of IL10secreting CD4 + T cells. This increase in IL10 might be indicative of increased Treg activity, especially given the advanced metastatic stage of LICRC patients. Our findings support the role of GARP/LAP as markers of IL10secreting Tregs, while coexpression of GARP/LAP also infer the potential of a TGFβ mediated suppressive mechanism of these cells.
Our data support the role of GARP and LAP as markers of Tregs, and potentially novel immunotherapy targets. GARPblocking antibodies have already been developed and shown to inhibit Treg activity in a xenogeneic model of graftversushostdisease [37] . In the absence of further clinical and functional data, we cannot comment on the exact nature and origin of FoxP3 +/-Helios + GARP + LAP + Tregs whether thymic or peripheral or even induced in the tumour microenvironment. Investigating the correlation between the levels of these Treg subsets and disease prognosis was not possible due to the relatively small number of samples, and it is imperative to investigate this correlation. Further studies are required to confirm the nature, origin and clinical impact of the FoxP3 +/-Helios + GARP + LAP + T cell subsets identified in this study. It will also be important to elucidate the role of Helios expression in Tregs and T cells, whether as an activation marker or as part of a suppressive mechanism.
Taken together, our results indicate that studies investigating Tregs in different pathological settings should consider different Tregrelated markers such as GARP, LAP, Helios, and not only FoxP3 as a sole Treg specific marker. Understanding the role and contribution of specific Treg subsets in various pathological settings will enable the development of effective immunotherapies, targeting only the most 'pathological' or suppressive Treg subsets as opposed to systemic therapies.
MATERIALS AND METHODS
Collection of blood samples
The research protocol was approved by the UK National Research Ethical Committee, Salford Research Ethics Committee and the Local Research and Development Departments. Written consent was obtained from all patients and healthy donors before blood collection. Samples were collected from patients with chronic pancreatitis (CP, n = 9), malignant pancreatic cancer (PC, n = 20) or liver metastases from colorectal cancer (LICRC, n = 11) at the North Manchester General Hospital, UK. Table 1 shows the characteristic features of all patients in this study. In addition, blood samples were collected from healthy donors (HD) as controls. Blood samples were collected in a 50 ml Falcon tube containing 200 μl (1000 IU/ml) heparin.
Cell isolation and preparation
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using FicollHypaque (Sigma Aldrich, UK) density gradient centrifugation. PBMCs were then frozen at 5-10 × 10 6 cells/ml in cryovials in 1 ml of freezing media (50% FCS, 40% RPMI1640 and 10% DMSO) and stored in liquid nitrogen (LN) for later use. Trypan blue was used for PBMC viability testing and counting.
In vitro T cell culture
PBMCs were thawed and suspended at 2 × 10 6 cells/ well in 2 ml complete medium [RPMI1640 supplemented with Lglutamine 2 mM, 10% FCS, Streptomycin 100 μg/ ml and Penicillin 100 Units/ml]. 24well nontreated culture plates were precoated with platebound 2 μg/ml antiCD3 antibody (OKT3 clone, eBioscience, Hatfield, UK) and 2 μg/ml antiCD28 antibody (CD28.2 clone, eBioscience) for 2.5 hours at 37°C. PBMCs were either plated as 'nonactivated' in noncoated wells or 'activated' in precoated wells. Plated cells were incubated for 18-20 hours in a humidified incubator at 37°C and 5% CO 2 . Cells were collected and blocked for FcR with IgG from human serum (SigmaAldrich), ready for staining and flow cytometric analysis.
Cell staining and flow cytometric analysis
Surface staining: Cells were then washed and labeled for surface markers: mouse antihuman CD4 PerCPCy5.5 (RPAT4 clone, eBioscience), mouse anti human CD3APCH7 (SK7 clone, BD Biosciences, Oxford, UK), mouse antihuman GARPAPC (7B11 clone, BD Biosciences), and mouse antihuman LAPPE (TW4-2F8 clone, BD Biosciences). Intracellular staining: Fixation, permeabilization and flow cytometry buffers were from eBioscience or BD Biosciences and prepared as per the manufacturer's instructions. Following staining for surface markers, cells were fixed and permeabilized at 4°C for 45 minutes using fixation/permeabilization buffer. Cells were then blocked for 15 minutes using rat serum (eBioscience) and mouse serum (SigmaAldrich) before staining with rat antihuman FoxP3PECy7 (PCH101 clone, eBioscience) and Armenian hamster antimouse/ human HeliosFITC (22F6 clone, Biolegend, Cambridge, UK) for 30 minutes at 4°C. Following two further permeabilization washes using permeablization buffer, cells were resuspended in flow cytometry buffer. Cytokine detection: Thawed PBMCs were plated in complete medium in a 24well nontreated culture plate precoated with 2 μg/ml antiCD3 and 2 μg/ml antiCD28. To investigate IFNγ and IL10 release from GARP +/-LAP +/-Treg subpopulations, cells were incubated for 24 hours at 37°C and 5% CO 2 . 1 μg/ml Golgi Plug (BD Biosciences) was added for the last 4 hours of activation. Cells were first stained for surface markers using mouse antihuman CD4 PerCPCy5.5, mouse antihuman CD3APCH7, mouse antihuman GARPAPC, and mouse antihuman LAPPE. For intracellular cytokines, cells were subsequently fixed, permeabilized and blocked using mouse serum before staining with mouse antihuman IL10FITC (BT10 clone, eBioscience) and mouse antihuman IFNγPECy7 (4S.B3 clone, BD Pharmingen, BD Biosciences, UK).
Flow cytometric data was acquired on FACSVerse or FACSCanto II flow cytometers (BD Biosciences, USA). www.impactjournals.com/oncotarget Data analysis was performed using BD FACSuite or FlowJo 10.0.8r1 software.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, USA). Paired T test or unpaired/MannWhitney tests were used to examine for differences within groups or between groups, respectively. P value ≤ 0.05 was considered statistically significant. The data are presented as means ± SEM.
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